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Using population-based linked health data, we investigated whether the risk of certain childhood non-CNS solid tumours (n¼186)
was associated with intra-uterine growth. The risk of retinoblastoma and rhabdomyosarcoma, but not other tumour types, was
positively associated with increased growth, suggesting a possible role of fetal growth factors. Larger studies are needed.
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Some childhood cancers occur more commonly in children below
the age of 5 years, suggesting that in utero factors may be
important in their aetiology. Birth weight has been frequently
studied in relation to risk, and is one of the few factors for which
positive associations have been reported. However, birth weight
studies of childhood non-central nervous system (non-CNS) solid
tumors have produced inconsistent results and few have taken
account of gestational age to differentiate between an association
with birth weight per se from one with accelerated intrauterine
growth. The mechanism(s) underlying the observed associations
has not been well elucidated, but insulin-like growth factors (IGFs)
have been implicated (LeRoith et al, 1991).
We previously reported an increased risk of ALL (acute
lymphocytic leukaemia) (Milne et al, 2007), of Hodgkin lymphoma
and Burkitt lymphoma among boys, and of non-Hodgkin
lymphoma among girls (Milne et al, 2008) in association with
increasing proportion of optimal birth weight, a measure of the
appropriateness of fetal growth (Blair et al, 2005). These findings
are consistent with a biologically plausible mechanism of
accelerated growth associated with growth factors in normal as
well as cancer cells. The aim of the present study was to investigate
whether the risk of non-CNS solid tumours was also associated
with fetal growth.
METHODS
We analysed anonymised, population-based data from the
Western Australian Data Linkage System (Holman et al, 1999).
Among births between 1980 and 2004, eligible subjects comprised
281 cases of non-CNS solid tumours below the age of 15 years and
576352 non-cases. We used cancer categories based on the
International Classification of Childhood Cancer, 3rd Edition
(ICCC3); only categories with more than 20 cases were included in
the analysis: neuroblastoma/ganglioneuroblastoma (hereafter
referred to as ‘neuroblastoma’) (n¼69), retinoblastoma (n¼38),
Wilms’ tumour (n¼52) and rhabdomyosarcoma (n¼27).
Explanatory variables included z-scores of ‘proportion of
optimal birth weight’ (POBW), ‘proportion of optimal birth length’
(POBL) and ‘proportion of optimal weight for length’ (POWFL)
(Blair et al, 2005); three measures of the appropriateness of intra-
uterine growth (IUG) described previously (Milne et al, 2007).
Briefly, POBW is the ratio of the observed to the ‘optimal birth
weight’; the latter estimated from a regression equation including
terms for gestational duration, maternal height, parity and infant
sex, derived from a total population of singleton births that
excluded those exposed to risk factors for IUG restriction,
including maternal smoking. POBL is the comparable measure of
the appropriateness of longitudinal growth, and primarily reflects
skeletal growth. POWFL is similarly derived and is a measure of
the appropriateness of total weight for length and predominately
reflects soft tissue growth. POBW, POBL and POWFL were
expressed as z-scores, so the risk of a specific tumour was
estimated per s.d., allowing direct comparison of regression
coefficients. The population means and s.d. used in the calculation
of the z-scores for each variable were those shown for the non-case
group in Table 1. Data were analysed using Cox proportional
hazards regression in STATA version 9.0 (StataCorp, 2005).
RESULTS
The sex distribution varied by type of tumour, with a higher
proportion of males than females with neuroblastoma and
retinoblastoma, more than half of which with were diagnosed
before 2 years of age. The proportion of first-born children was
higher in each tumour group than in the non-case group (Table 1).
The risk of retinoblastoma (HR: 0.54) was lower among girls
than boys (Table 2). Overall, there was little evidence of an
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neuroblastoma or Wilms’ tumour. There appeared to be weak
positive associations between POBW and retinoblastoma (HR:
1.22) and rhabdomyosarcoma (HR: 1.33) (Table 2). Similarly,
POBL appeared to be positively associated with retinoblastoma
(HR: 1.26) and POWFL with rhabdomyosarcoma (HR: 1.41)
(Table 2), though few associations were statistically significant.
As in our approach with childhood ALL (Milne et al, 2007), CNS
tumors and lymphomas (Milne et al, 2008), we aimed to
distinguish an effect of high birth weight per se and one with
accelerated growth. We restricted the univariate regression
analysis of POBW to, in turn, children with birth weights below
two commonly used definitions of high birth weight: 43500 and
44000g. The positive associations observed between POBW and
retinoblastoma and rhabdomyosarcoma were also observed among
children with birth weights o3500 and o4000g: retinoblastoma
(HR: 1.39, 95% CI 0.82–2.36 and HR: 1.32, 95% CI 0.89–1.95,
respectively); and rhabdomyosarcoma (HR: 1.53, 95% CI 0.82–
2.86 and HR: 1.55, 95% CI 1.00–2.40, respectively).
DISCUSSION
Our measures of the appropriateness of fetal growth – POBL,
POBW and POWFL – are independent of gestational age and take
account of the major non-pathological determinants of IUG. As
with ALL (Milne et al, 2007) and lymphomas (Milne et al, 2008),
there was a positive association between at least one measure of
IUG and risk of retinoblastoma and rhabdomyosarcoma. We
found no evidence of an association between IUG and risk of
neuroblastoma and, unlike previous studies (Leisenring et al, 1994;
Yeazel et al, 1997; Schuz et al, 2001), we found no association
between IUG and the risk of Wilm’s tumour.
Growth is a mixture of skeletal growth – tending to be expressed
as increased height; and somatic growth, which may be propor-
tionate (ie, a large child, but with a normal body mass index), or
disproportionate (increased soft tissue with a raised body mass
index/POWFL). Insulin-like growth factors play a major role in
regulating the normal growth and differentiation of cells and
tissues during fetal development (LeRoith et al, 1991). Some
tumours produce IGF-I, IGF-II or their binding proteins, or
possess IGF receptors (Campbell and Novak, 1991; Antoniades
et al, 1992; Hirschfeld and Helman, 1994; Boulle et al, 1998). IGF-I,
in particular, inhibits the process of programmed cell death in
both normal and DNA-damaged cells (Barres et al, 1992; Baserga
et al, 1997a). The mitotic properties of IGFs, coupled with their
ability to inhibit cell death, are thought to enhance tumour growth
(Baserga et al, 1997b; Werner and Le Roith, 2000; Bentov and
Werner, 2004; Pollak et al, 2004). Different tumours are likely to
have different underlying genetic predispositions, which in turn
are likely to be reflected in different patterns of growth, which may
partly explain the associations we observed.
This study has some important strengths. Examining risk
associated with the appropriateness of IUG allows a more detailed
exploration of this relationship than using birth weight alone or
birth weight with adjustment for gestational age. We were able to
explore associations between some specific solid cancers of
childhood and three distinct aspects of IUG: POBW, POBL and
POWFL. The z-scores for each of these were modeled appro-
priately as continuous variables and this method obviated the need
to assign an arbitrary cutoff for ‘high birth weight’. Being a
population-based, record-linkage study, neither selection bias nor
recall bias would have affected our results.
There were small numbers of cases in this study and many
results were only suggestive of an association; however, our
findings are consistent with literature describing biologically
plausible mechanisms for associations between increased fetal
growth and risk of some non-CNS solid tumours. The persistence
of our results when the analysis was restricted to children without
high birth weight further supports an association with accelerated
growth, rather than high birth weight per se.
We recommend for future studies, the use of measures of the
appropriateness of IUG rather than birth weight alone, particularly
Table 1 Descriptive characteristics of non-CNS solid tumours in children aged 0–14 years in Western Australia
Sex Age at diagnosis Birth order
POBW POBL POWFL
N
Males
N (%)
Females
N (%)
o2 years
N (%)
2+ years
N (%)
First born
N (%)
Subsequent
born N (%) Mean (s.d.) Mean (s.d.) Mean (s.d.)
Non-cases 576352 293766 282586 — — 295903 280449
(51.0) (49.0) (51.3) (48.7) 97.5 (12.5) 99.5 (4.5) 97.6 (10.4)
Neuroblastoma 69 40 (58.0) 29 (42.0) 39 (56.5) 30 (43.5) 36 (52.2) 33 (47.8) 98.6 (13.9) 99.7 (5.0) 98.3 (10.7)
Retinoblastoma 38 25 (65.8) 13 (34.2) 23 (60.5) 15 (39.5) 21 (55.3) 17 (44.7) 100.1 (11.2) 100.6 (5.3) 99.3 (9.6)
Wilms’ tumour 52 25 (48.1) 27 (51.9) 20 (38.5) 32 (61.5) 30 (57.7) 22 (42.3) 98.7 (13.6) 99.2 (4.2) 98.4 (10.6)
Rhabdomyosarcoma 27 13 (48.2) 14 (51.8) 9 (33.3) 18 (66.7) 16 (59.3) 11 (40.7) 101.3 (10.7) 99.5 (3.6) 101.3 (9.5)
non-CNS¼non-central nervous system; POBW¼proportion of optimal birth weight; POBL¼proportion of optimal birth length; POWFL¼proportion of optimal weight for
length.
Table 2 Cox univariate regression analysis of non-CNS solid tumours in children aged 0–14 years in Western Australia
Female sex Not first born POBW z-score POBL z-score POWFL z-score
HR CI HR CI HR CI HR CI HR CI
Neuroblastoma 0.75 (0.47,1.22) 0.98 (0.61,1.57) 1.09 (0.86,1.38) 1.04 (0.82,1.32) 1.07 (0.85,1.36)
Retinoblastoma 0.54 (0.28,1.06) 0.86 (0.46,1.64) 1.22 (0.90,1.66) 1.26 (0.92,1.72) 1.18 (0.86,1.60)
Wilms’ tumour 1.12 (0.65,1.94) 0.80 (0.46,1.39) 1.10 (0.84,1.44) 0.93 (0.71,1.22) 1.08 (0.82,1.42)
Rhabdomyosarcoma 1.12 (0.53,2.38) 0.75 (0.35,1.62) 1.33 (0.93,1.90) 0.99 (0.68,1.44) 1.41 (0.98,2.01)
HR¼hazard Ratio; CI¼95% confidence interval; POBW¼proportion of optimal birth weight; POBL¼proportion of optimal birth length; POWFL¼proportion of optimal
weight for length.
Fetal growth and childhood non-CNS solid tumours
CL Laurvick et al
180
British Journal of Cancer (2008) 99(1), 179–181 & 2008 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yin large collaborative studies that can examine these relationships
with greater power.
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